We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Shield Therapeutics Plc | STX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.10 | -6.06% | 1.55 | 16:15:29 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.65 | 1.475 | 1.65 | 1.55 | 1.65 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 30/4/2024 08:20 by wheeze A lot of hot air being blown about - this is a pharmaceutical company with a stellar product for the treatment of a common condition prevalent worldwide. Buying a penny share today won't be a get rich quick scheme if you are a trader, however if you are a long term investor, this could be a potential winner. A fifty bagger would give you a market cap of 500 million which would be ridiculously low if this takes hold. One for the bottom drawer. Invest what you can afford to lose, ignore the bulletin board chatter and come back in ten years. |
Posted at 29/4/2024 10:05 by napoleon 14th This is a reminder that SHIELD THERAPEUTICS PLC will be holding the meeting Final results for the year ended 31 December 2023 tomorrow at 30th Apr 2024 at 2:30pm BST.Please click on the button below accept the meeting invitation. Should you have any questions, please contact support@investormeet Kind Regards, The Team at Investor Meet Company |
Posted at 25/4/2024 12:09 by reviewwworld The share price sadly indicates otherwise.If there is one thing we have learnt about this sinking ship is that it's a very leaky one. Every single announcement by the company of the past 2 years has seen selling beforehand that has proven to be "smart" sales.This move today, in decent volume, just confirms the narrative. Every announcement I report to the FCA for insider dealing but yet to receive a response/investigati |
Posted at 23/4/2024 19:19 by razoblade Edison wrong, misled or exaggerated the research. Surly if the company starts to miss quarterly figures and you keep egging it on, you are partly to blame as investors use such research papers to get some insight into the business. |
Posted at 05/3/2024 20:32 by tripletop1 Absolutely gobsmacked there's still no TR1's!!There's been huge amounts of stock that's been offloaded and changed hands since before Christmas - coupled with the 167m on the Trading update are we saying all the institutional investors @3%+ are still onboard? Have AOP dumped any? Just doesn't add up.. |
Posted at 27/2/2024 22:33 by bones699 I think the share price here could easily double..Let's face it I invested in Angle Plc which basically is a hopeless money cess pit costing £140m to date ffs with absolutely zero chance of success and led by a a habitual lying bar steward of a CEO who mugs retail investors for a living! |
Posted at 27/2/2024 13:26 by qipincha Nope, the company will not finish. But market panic when there is uncertainties. Also, the CEO has not won investors support in recent years.Saying that, the company still has a good product and currently making approx 4-5m income per quarter and growing. The question is if they have a good saving plan to go through 2024 without asking for further funding. They properly realise it already, hence they mentioned a lot about saving in the recent meeting. Based on my calculation, if they can keep the cost below 3m per month, they should be able to survive. |
Posted at 21/2/2024 19:46 by bolitix Why are you tracking my posts. Get a life! I remember you saying this CEO was a good move! Then sold out and bought back in. I am the only one here that has maintained this CEO is a donkey. At some point one of the big investors will boot the donkey out. How much is the $10m (bought at 8p) investment AOP made now!! |
Posted at 08/12/2023 10:52 by ekcs That may well be the case but it's the sentiment and therefore the expectation that they've created from their more recent IR disasters that concerns investors when they look forwards which is the point I'm making. It's going to take time for investors to develop enough trust in them to cause a reversal to the positive. The CEO could stick his hand in his pocket as well as that would only help sentiment instead of simply scooping up options that are only time delayed rather than actually having some decent performance conditions attached. Perhaps he could use some of the £350k bonus he got last year!!! |
Posted at 06/9/2023 07:03 by hamhamham1 Shield Therapeutics plc("Shield" or the "Company" or the "Group") Notice of interim results Change in reporting currency London, UK, 6 September 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru® (ferric maltol), will announce its interim results for the six months ended 30 June 2023 on Thursday 28 September 2023. Investor presentation CEO, Greg Madison, and CFO, Hans-Peter Rudolf, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 16.30 (BST) on Thursday 28 September 2023. The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 (BST) the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via: Investors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited. Change in reporting currency Reflecting the increasing importance of the Group's U.S. operations on its financial results, Shield is also announcing that it will change its reporting currency from Pounds Sterling to US Dollars (USD) effective 1 January 2023.The interim results for the six months ending 30 June 2023 will include condensed, consolidated USD financial information for H123 and FY22. In accordance with the relevant accounting standards, comparative historic financial information for FY 2022 will be published in USD alongside the full FY 2023 results in the first half of 2024. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
